Metraipolis › archive › dc_cb299dfb79f1

Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China — Europe PMC PMID:42518819

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42518819
DOI
10.3389/fonc.2026.1889698
License (as archived)
solo-consultazione
Archived
2026-10-18T11:04:48.594Z
SHA-256 of the archived text
f384a2c4516231e6666ba83a103d72724a293f3e5bdaf3461fd7a2442492a5da
Stable URL of this page
https://metraipolis.com/documento/dc_cb299dfb79f1

How to cite

Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China — Europe PMC PMID:42518819 — Europe PMC (en), https://europepmc.org/article/MED/42518819 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cb299dfb79f1 (Metraipolis archive dc_cb299dfb79f1, sha256 f384a2c4516231e6666ba83a103d72724a293f3e5bdaf3461fd7a2442492a5da)
BibTeX
@misc{dccb299dfb79f1,
  title = {Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China — Europe PMC PMID:42518819},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42518819},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cb299dfb79f1; sha256 f384a2c4516231e6666ba83a103d72724a293f3e5bdaf3461fd7a2442492a5da},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42518819. Agents can read the archived copy with the MCP tool read_document.